Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore function worldwide. The company’s therapeutic candidates include DIABECELL, which is in late-stage clinical trials for the treatment of type 1 diabetes; and NTCELL, which is in Phase I/IIa clinical trials for the treatment of Parkinson’s disease. It has a collaboration agreement with the Centre for Brain Research to identify neurodegenerative disease targets for clinical studies of NTCELL product. The company was founded in 1987 and is based in Auckland, New Zealand.
living cell technologies ltd
(LCT:Australian Stock Exchange Ltd)
PO Box 23566
Phone: 64 9 276 2690
Fax: 64 9 276 2691www.lctglobal.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for LCT.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact LIVING CELL TECHNOLOGIES LTD, please visit www.lctglobal.com. Company data is provided by Capital IQ. Please use this form to report any data issues.